Ovarian Cancer

Enrollment restarts in a phase 2 ovarian and clear cell gynecologic cancer study after FDA lifts hold on PD-1/CTLA-4 DART therapy.

Mirvetuximab soravtansine plus carboplatin showed promise in patients with FRα-positive platinum-sensitive ovarian cancer.

The novel FRα-targeted ADC sofetabart mipitecan showed strong antitumor activity in patients with heavily pretreated platinum-resistant ovarian cancer.

Final ROSELLA overall survival results show adding relacorilant to nab-paclitaxel reduces risk of death by 35% in platinum-resistant ovarian cancer.

FDA grants fast track designation to SIM0505, a CDH6-targeting ADC, for platinum-resistant ovarian cancer. Phase 1 data expected at ASCO 2026.

FDA fast track status for CTIM-76 underscores the unmet need in platinum-resistant ovarian cancer.

ZW191 is engineered to bind to FRα, a cell-surface protein with high expression across several tumor types.

Final results from the phase 2 OVATION 2 trial show that adding IMNN-001 to standard chemotherapy significantly improves overall survival in newly diagnosed advanced ovarian cancer.

FDA approves relacorilant for platinum-resistant ovarian cancer, showing significant survival benefits without added safety risks in clinical trials.

FDA clears MyChoice CDx to find HRD-positive advanced ovarian cancer patients for niraparib, using BRCA and genomic instability testing.

Clinical trial data show ovarian cancer survival gaps narrow with diverse enrollment, but disparities persist after progression, spotlighting access, toxicity, and care barriers.

Phase 2 data show elenagen plus gemcitabine extends survival in platinum-resistant ovarian cancer with high CA-125, without added toxicity.

FDA approves pembrolizumab with chemotherapy for platinum-resistant ovarian cancer, showing significant survival benefits in clinical trials.

A recent study reveals significant racial disparities in ovarian cancer trial outcomes, highlighting the urgent need for improved diversity in clinical research.

Gemogenovatucel-T shows remarkable survival benefits in high-risk ovarian cancer patients, highlighting its potential as a new standard of care.

BioInvent's BI-1808 combined with pembrolizumab shows promising antitumor activity in recurrent ovarian cancer, offering hope for better treatment options.

The ROSELLA trial reveals relacorilant plus nab-paclitaxel significantly improves survival in platinum-resistant ovarian cancer without increasing safety risks.

New cancer vaccine MVP-S shows promising results in recurrent ovarian cancer, enhancing immune response and improving treatment outcomes with pembrolizumab.

Sofetabart mipitecan receives FDA breakthrough therapy designation, showing promising efficacy in treating platinum-resistant ovarian cancer.

The SCORES trial reveals suvemcitug significantly enhances survival and disease control in patients with platinum-resistant recurrent ovarian cancer.

A systematic review reveals PARP inhibitors improve progression-free survival in advanced ovarian cancer but lack overall survival benefits, highlighting treatment variability.

ETX-19477 receives FDA fast track designation, promising accelerated development for treating BRCA-mutated, platinum-resistant ovarian cancer patients.

A novel antibody combination shows promising results in treating recurrent ovarian cancer, offering hope for better immunotherapy options.

A phase 2 trial shows ribociclib and letrozole effectively treat recurrent low-grade serous carcinoma, achieving significant response rates and durable control.